Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pasritamig plus docetaxel versus docetaxel in metastatic castration-resistant prostate cancer
jRCT2031250582Phase 3Recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Feb 2026
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
01
Overview
Phase 3, randomised, open-label trial in prostate cancer (PCa) comparing Pasritamig+Docetaxel with Docetaxel (2 arms). Primary endpoint: Radiographic progression-free survival. Started Feb 2026; status: recruiting.
02
Drugs
pasritamigdocetaxel
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on jRCT2031250582.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031250582.